Pharma BD Deal Intelligence
A $5.4B all-cash deal that let Siemens fold Bayer Diagnostics into a chronically underperforming Healthineers Diagnostics unit — a 2010 impairment and years of low-single-digit margins later, Siemens is reportedly shopping the whole division for roughly what it originally paid.
Bayer Diagnostics became the core of a chronically underperforming Siemens/Healthineers Diagnostics unit that took a $1.5B+ impairment and, ~18 years later, Siemens is reportedly trying to sell the whole business for roughly what it originally paid.
Full analysis, sources & comparables →Combined with the DPC acquisition, the Bayer deal would make Siemens the third-largest IVD provider globally with 13% market share, behind Roche (22%) and…
Siemens to buy Bayer's diagnostics arm for EUR 4.2 billion, giving the German conglomerate a leading position in clinical chemistry and entry into molecular…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
In vitro diagnostics; EUR 4.2B; closed early 2007
Bayer Diagnostics became the core of a chronically underperforming Siemens/Healthineers Diagnostics unit that took a $1.5B+ impairment and, ~18 years later, Siemens is reportedly trying to sell the whole business for roughly what it originally paid.
Assessment window: 15yr post-close.
$1.8B Bayer Diagnostics FY2005 sales (EUR 1.4B)
In vitro diagnostics (IVD) covers laboratory tests on blood, tissue, and other specimens used to detect disease, monitor therapy, and guide clinical decisions. Clinical chemistry, immunoassays, hematology, and molecular diagnostics are the largest segments, with growth driven by aging populations, point-of-care testing, and gene-based assays.
At the time of the 2006 deal, the global IVD market was led by Roche Diagnostics (~22% share, anchored by Cobas clinical chemistry and Ampliprep molecular platforms) and Abbott Diagnostics (~14%, with Architect immunoassay systems and m2000 molecular). Bayer Diagnostics was a top-five player with leadership in clinical chemistry, near-patient testing, and the Versant nucleic-acid testing line for HIV/HCV. Other competitors included Beckman Coulter (Synchron clinical chemistry, Access immunoassay), Bio-Rad, Dade Behring, and Ortho Clinical Diagnostics. Combined with Siemens' April 2006 acquisition of Diagnostic Products Corporation (DPC), the Bayer deal vaulted Siemens Medical Solutions to the #3 IVD position globally with ~13% share and made it #2 in immunodiagnostics, while creating the industry's first vendor able to span imaging diagnostics, lab diagnostics, and clinical IT under one roof. The strategic logic was integrated diagnostics: pairing imaging modalities (CT, MR) with molecular and lab assays to enable disease-management workflows and personalized medicine. The deal also intensified consolidation pressure on mid-tier IVD players, foreshadowing the 2007 Siemens-Dade Behring transaction. Source: https://healthcare-in-europe.com/en/news/siemens-to-acquire-bayer-s-diagnostics-division.html
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Siemens AG / Bayer Diagnostics (this deal) | 2006 | $5.4B | 38 |
| Siemens AG / Diagnostic Products Corporation | 2006 | $1.9B | 48 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |
| Genentech, Inc. (Roche Group) / Tanox Inc. | 2006 | $919M | 80 |
← Browse all deals · How we score deals
More: 2006 deals